Logo

FDA Clears Hologic MDx Assay for Gastrointestinal Illness

Jan 23, 2013 | staff reporter

NEW YORK (GenomeWeb News) – Hologic said today that the US Food and Drug Administration has cleared its Prodesse ProGastro SSCS assay for marketing in the US.

Hologic acquired the technology when it bought Gen-Probe last summer. The real-time, multiplex PCR assay is for the qualitative detection of Salmonella, Shigella, and Campylobacter (C. jejuni and C.coli only undifferentiated) nucleic acids and Shiga Toxin 1 (stx1) and Shiga Toxin 2 (stx2) genes.

Hologic said the assay runs on a common benchtop instrument available in many labs and will provide results in hours. By comparison, culture tests may take 48 hours or more for results.

Filed under

PCR
Diagnostics
Molecular Diagnostics
Regulatory News & FDA Approvals
Hologic
FDA clearance
FDA
PCR-based diagnostics
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.